CGEM
Cullinan Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Cullinan Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+1.93%
vs ±23.3% implied · ×0.08
shaded = implied · ▲▼ = realized
No thesis.
Fund move
Fund move
Cullinan Therapeutics, Inc.
15.06
−0.39 · −2.53%
post 14.90 −1.06%
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | MPM Oncology Impact ManagementMPM Oncology Impact | $177.2M | 13.52% | +27.24% | |
| 2 | Lynx1 Capital ManagementLynx1 | $163.2M | 12.45% | 0.00% | |
| 3 | BVFBVF | $104.7M | 7.99% | 0.00% | |
| 4 | BlackRockBlackRockindex-like | $95.3M | 7.27% | +17.59% | |
| 5 | T. Rowe Price AssociatesT. Rowe Price | $69.7M | 5.32% | +88.50% | |
| 6 | State StreetState Streetindex-like | $66.8M | 5.10% | +44.20% | |
| 7 | Kynam Capital ManagementKynam | $56.7M | 4.33% | 0.00% | |
| 8 | Vanguard Capital ManagementVanguardindex-like | $47.6M | 3.63% | +5.28% | |
| 9 | RTW InvestmentsRTW | $43.1M | 3.29% | +38.59% | |
| 10 | SirenSiren | $34.5M | 2.63% | +58.66% | |
| 11 | Geode Capital ManagementGeodeindex-like | $28.2M | 2.15% | +13.09% | |
| 12 | Blue Owl Capital HoldingsBlue Owl Capital | $28.0M | 2.14% | −19.37% | |
| 13 | VR AdviserVR Adviser | $25.1M | 1.92% | 0.00% | |
| 14 | Boothbay Fund ManagementBoothbay Fund | $19.7M | 1.50% | −2.71% | |
| 15 | Dimensional Fund AdvisorsDimensional | $19.1M | 1.45% | +15.53% | |
| 16 | Goldman Sachs GroupGoldman Sachs | $18.2M | 1.39% | +119.91% | |
| 17 | Affinity Asset AdvisorsAffinity Asset | $15.9M | 1.22% | +12.10% | |
| 18 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $13.5M | 1.03% | +33.70% | |
| 19 | Boone Capital ManagementBoone | $12.8M | 0.98% | new | |
| 20 | Elmind CapitalElmind Capital | $12.6M | 0.96% | +30.19% | |
| 21 | Morgan StanleyMorgan Stanley | $11.5M | 0.87% | +6.71% | |
| 22 | Twin Focus Capital PartnersTwin Focus Capital Partners | $10.8M | 0.83% | 0.00% | |
| 23 | AQR Capital ManagementAQR | $10.6M | 0.81% | +61.09% | |
| 24 | Northern TrustNorthern Trustindex-like | $10.4M | 0.79% | +27.12% | |
| 25 | Citadel AdvisorsCitadel | $9.3M | 0.71% | +75.52% |
184 managers report $1.3B of Cullinan Therapeutics on form 13F for the quarter ended Jun 30 '26. 20 of them hold 80% of it; MPM Oncology Impact is largest at 13.52%.
No implied move.
No implied move.
Expected move
No implied move.